{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T04:12:39Z","timestamp":1789704759070,"version":"4.0.1"},"reference-count":44,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Research in Veterinary Science"],"published-print":{"date-parts":[[2019,6]]},"DOI":"10.1016\/j.rvsc.2019.03.018","type":"journal-article","created":{"date-parts":[[2019,3,22]],"date-time":"2019-03-22T03:06:15Z","timestamp":1553223975000},"page":"233-238","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"special_numbering":"C","title":["In-vitro binding analysis of anti-human vascular endothelial growth factor antibodies bevacizumab and aflibercept with canine, feline, and equine vascular endothelial growth factor"],"prefix":"10.1016","volume":"124","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0969-8065","authenticated-orcid":false,"given":"Lisa-Marie","family":"Muellerleile","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernhard","family":"Buxbaum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Nell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela A.","family":"Fux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"17","key":"10.1016\/j.rvsc.2019.03.018_bb0005","doi-asserted-by":"crossref","first-page":"3389","DOI":"10.1093\/nar\/25.17.3389","article-title":"Gapped BLAST and PSI-BLAST : a new generation of protein database search programs","volume":"25","author":"Altschul","year":"1997","journal-title":"Nucleic Acids Res."},{"issue":"1","key":"10.1016\/j.rvsc.2019.03.018_bb0010","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1002\/1099-1352(200101\/02)14:1<62::AID-JMR520>3.0.CO;2-T","article-title":"Predicting the kinetics of peptide-antibody interactions using a multivariate experimental design of sequence and chemical space","volume":"14","author":"Andersson","year":"2001","journal-title":"J. Mol. Recognit."},{"issue":"4","key":"10.1016\/j.rvsc.2019.03.018_bb0015","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/j.ophtha.2006.12.028","article-title":"Primary intravitreal bevacizumab (Avastin) for diabetic macular edema. Results from the pan-American collaborative retina study group at 6-month follow-up","volume":"114","author":"Arevalo","year":"2007","journal-title":"Ophthalmology"},{"issue":"3","key":"10.1016\/j.rvsc.2019.03.018_bb0020","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.ophtha.2005.11.019","article-title":"Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration","volume":"113","author":"Avery","year":"2006","journal-title":"Ophthalmology"},{"issue":"4","key":"10.1016\/j.rvsc.2019.03.018_bb0025","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1111\/j.1463-5224.2011.00973.x","article-title":"Expression of vascular endothelial growth factor receptor-1 and -2 in normal and diseased canine eyes","volume":"15","author":"Binder","year":"2012","journal-title":"Vet. Ophthalmol."},{"issue":"10","key":"10.1016\/j.rvsc.2019.03.018_bb0030","doi-asserted-by":"crossref","first-page":"2044","DOI":"10.1016\/j.ophtha.2015.06.017","article-title":"Intravitreal aflibercept for diabetic macular edema: 100-week results from the VISTA and VIVID studies","volume":"122","author":"Brown","year":"2015","journal-title":"Ophthalmology"},{"key":"10.1016\/j.rvsc.2019.03.018_bb0035","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1146\/annurev-cellbio-092910-154002","article-title":"Developmental and pathological angiogenesis","volume":"27","author":"Chung","year":"2011","journal-title":"Annu. Rev. Cell Dev. Biol."},{"issue":"4","key":"10.1016\/j.rvsc.2019.03.018_bb0040","first-page":"362","article-title":"Stromal vascularization prevents corneal ulceration","volume":"19","author":"Conn","year":"1980","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"issue":"12","key":"10.1016\/j.rvsc.2019.03.018_bb0045","first-page":"2485","article-title":"Loss and restoration of immune privilege in eyes with corneal neovascularization","volume":"37","author":"Dana","year":"1996","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"issue":"4","key":"10.1016\/j.rvsc.2019.03.018_bb0050","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1001\/archophthalmol.2009.18","article-title":"Topical bevacizumab in the treatment of corneal neovascularization: results of a prospective, open-label, non-comparative study","volume":"127","author":"Dastjerdi","year":"2009","journal-title":"Arch. Ophthalmol."},{"issue":"8","key":"10.1016\/j.rvsc.2019.03.018_bb0055","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1177\/1098612X12472181","article-title":"Feline eosinophilic keratoconjunctivitis: a retrospective study of 45 cases (56 eyes)","volume":"15","author":"Dean","year":"2013","journal-title":"J. Feline Med. Surg."},{"issue":"4","key":"10.1016\/j.rvsc.2019.03.018_bb0060","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1097\/00003226-198706040-00004","article-title":"Corneal neovascularization. Pathogenesis and inhibition","volume":"6","author":"Epstein","year":"1987","journal-title":"Cornea"},{"issue":"1","key":"10.1016\/j.rvsc.2019.03.018_bb0065","doi-asserted-by":"crossref","first-page":"105","DOI":"10.2460\/javma.1998.213.01.105","article-title":"Clinical appearances, healing patterns, risk factors, outcomes of horses with fungal keratitis: 53 cases (1978-1996)","volume":"213","author":"Gaarder","year":"1998","journal-title":"J. Am. Vet. Med. Assoc."},{"issue":"4","key":"10.1016\/j.rvsc.2019.03.018_bb0070","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1111\/j.1463-5224.2005.00393.x","article-title":"Immune-mediated keratitis in horses: 19 cases (1998-2004)","volume":"8","author":"Gilger","year":"2005","journal-title":"Vet. Ophthalmol."},{"issue":"7","key":"10.1016\/j.rvsc.2019.03.018_bb0075","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1016\/j.ophtha.2014.01.027","article-title":"Intravitreal aflibercept injection for macular edema due to central retinal vein occlusion: two-year results from the COPERNICUS study","volume":"121","author":"Heier","year":"2014","journal-title":"Ophthalmology"},{"issue":"Suppl. 1","key":"10.1016\/j.rvsc.2019.03.018_bb0080","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1111\/vop.12102","article-title":"Equine deep stromal abscesses (51 cases - 2004-2009) - part 2: the histopathology and immunohistochemical aspect with attention to the histopathologic diagnosis, vascular response, and infectious agents","volume":"17","author":"Henriksen","year":"2014","journal-title":"Vet. Ophthalmol."},{"issue":"17","key":"10.1016\/j.rvsc.2019.03.018_bb0085","doi-asserted-by":"crossref","first-page":"11393","DOI":"10.1073\/pnas.172398299","article-title":"VEGF-trap: a VEGF blocker with potent antitumor effects","volume":"99","author":"Holash","year":"2002","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"6","key":"10.1016\/j.rvsc.2019.03.018_bb0090","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1016\/j.ophtha.2015.01.025","article-title":"Intravitreal aflibercept injection in patients with myopic choroidal neovascularization: the MYRROR study","volume":"122","author":"Ikuno","year":"2015","journal-title":"Ophthalmology"},{"issue":"3","key":"10.1016\/j.rvsc.2019.03.018_bb0095","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/S0195-5616(90)50052-2","article-title":"A new perspective on canine keratoconjunctivitis sicca: treatment with ophthalmic cyclosporine","volume":"20","author":"Kaswan","year":"1990","journal-title":"Vet. Clin. N. Am. Small Anim. Pract."},{"issue":"6","key":"10.1016\/j.rvsc.2019.03.018_bb0100","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.ophtha.2008.02.013","article-title":"The effect of topical bevacizumab on corneal neovascularization","volume":"115","author":"Kim","year":"2008","journal-title":"Ophthalmology"},{"key":"10.1016\/j.rvsc.2019.03.018_bb0105","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1007\/s00417-009-1099-1","article-title":"Short- and long-term safety profile and efficacy of topical bevacizumab (Avastin\u00ae) eye drops against corneal neovascularization","volume":"247","author":"Koenig","year":"2009","journal-title":"Graefes Arch. Clin. Exp. Ophthalmol."},{"key":"10.1016\/j.rvsc.2019.03.018_bb0110","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2014\/178132","article-title":"Treatment of corneal neovascularization using anti-VEGF bevacizumab","volume":"2014","author":"Krizova","year":"2014","journal-title":"J. Ophthalmol."},{"issue":"5","key":"10.1016\/j.rvsc.2019.03.018_bb0115","doi-asserted-by":"crossref","first-page":"667","DOI":"10.2460\/javma.243.5.667","article-title":"Characteristics of, prevalence of, and risk factors for corneal pigmentation (pigmentary keratopathy) in pugs","volume":"243","author":"Labelle","year":"2013","journal-title":"J. Am. Vet. Med. Assoc."},{"issue":"3","key":"10.1016\/j.rvsc.2019.03.018_bb0120","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/j.ophtha.2011.01.041","article-title":"Horizons in therapy for corneal angiogenesis","volume":"118","author":"Maddula","year":"2011","journal-title":"Ophthalmology"},{"issue":"7","key":"10.1016\/j.rvsc.2019.03.018_bb0125","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1016\/j.ophtha.2012.03.053","article-title":"Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results","volume":"119","author":"Martin","year":"2012","journal-title":"Ophthalmology"},{"issue":"6","key":"10.1016\/j.rvsc.2019.03.018_bb0130","doi-asserted-by":"crossref","first-page":"3396","DOI":"10.4049\/jimmunol.163.6.3396","article-title":"Fc-mediated nonspecific binding between fibronectin-binding protein I of Streptococcus pyogenes and human immunoglobulins","volume":"163","author":"Medina","year":"1999","journal-title":"J. Immunol."},{"issue":"10","key":"10.1016\/j.rvsc.2019.03.018_bb0135","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1016\/S0969-2126(97)00284-0","article-title":"The crystal structure of vascular endothelial growth factor (VEGF) refined to 1.93 \u00c5 resolution : multiple copy flexibility and receptor binding","volume":"5","author":"Muller","year":"1997","journal-title":"Structure"},{"issue":"8","key":"10.1016\/j.rvsc.2019.03.018_bb0140","first-page":"1758","article-title":"Experimental ocular herpesvirus infection in the cat","volume":"30","author":"Nasisse","year":"1989","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"issue":"1","key":"10.1016\/j.rvsc.2019.03.018_bb0145","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1111\/j.1463-5224.2005.04062.x","article-title":"The effect of topical pimecrolimus on keratoconjunctivitis sicca and chronic superficial keratitis in dogs: results from an exploratory study","volume":"8","author":"Nell","year":"2005","journal-title":"Vet. Ophthalmol."},{"issue":"1","key":"10.1016\/j.rvsc.2019.03.018_bb0150","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1006\/jmbi.2000.4042","article-title":"T-Coffee : a novel method for fast and accurate multiple sequence alignment","volume":"302","author":"Notredame","year":"2000","journal-title":"J. Mol. Biol."},{"issue":"4","key":"10.1016\/j.rvsc.2019.03.018_bb0155","doi-asserted-by":"crossref","first-page":"209","DOI":"10.5935\/0004-2749.20140054","article-title":"Comparison of the effects of subconjunctival and topical anti-VEGF therapy (bevacizumab) on experimental corneal neovascularization","volume":"77","author":"Ozdemir","year":"2014","journal-title":"Arq. Bras. Oftalmol."},{"key":"10.1016\/j.rvsc.2019.03.018_bb0160","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/s10456-011-9249-6","article-title":"Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF trap ranibizumab and bevacizumab","volume":"15","author":"Papadopoulos","year":"2012","journal-title":"Angiogenesis"},{"key":"10.1016\/j.rvsc.2019.03.018_bb0165","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1136\/bjo.66.11.705","article-title":"Corticosteroids and corneal epithelial wound healing","volume":"66","author":"Petroutsos","year":"1982","journal-title":"Br. J. Ophthalmol."},{"key":"10.1016\/j.rvsc.2019.03.018_bb0170","first-page":"4593","article-title":"Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders","volume":"57","author":"Presta","year":"1997","journal-title":"Cancer Res."},{"key":"10.1016\/j.rvsc.2019.03.018_bb0180","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1111\/j.1748-5827.2006.00185.x","article-title":"Canine keratoconjunctivitis sicca : disease trends in a review of 229 cases","volume":"48","author":"Sanchez","year":"2007","journal-title":"J. Small Anim. Pract."},{"key":"10.1016\/j.rvsc.2019.03.018_bb0185","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.exer.2016.03.021","article-title":"Efficacy of topical aflibercept versus topical bevacizumab for the prevention of corneal neovascularization in a rat model","volume":"146","author":"Sella","year":"2016","journal-title":"Exp. Eye Res."},{"issue":"12","key":"10.1016\/j.rvsc.2019.03.018_bb0195","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1111\/j.1748-5827.1977.tb05852.x","article-title":"Ueberreiter's syndrome (chronic superficial keratitis) in dogs in the Rocky Mountain area - a study of 463 cases","volume":"18","author":"Slatter","year":"1977","journal-title":"J. Small Anim. Pract."},{"issue":"9","key":"10.1016\/j.rvsc.2019.03.018_bb0200","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1111\/ceo.12559","article-title":"Aflibercept for the treatment of neovascular glaucoma","volume":"43","author":"SooHoo","year":"2015","journal-title":"Clin. Exp. Ophthalmol."},{"issue":"2","key":"10.1016\/j.rvsc.2019.03.018_bb0205","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1111\/j.1463-5224.2008.00679.x","article-title":"Treatment of proliferative feline eosinophilic keratitis with topical 1.5% cyclosporine: 35 cases","volume":"12","author":"Spiess","year":"2009","journal-title":"Vet. Ophthalmol."},{"issue":"13","key":"10.1016\/j.rvsc.2019.03.018_bb2005","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1056\/NEJMoa1414264","article-title":"Aflibercept, Bevacizumab, or Ranibizumab for Diabetic Macular Edema","volume":"372","author":"The Diabetic Retinopathy Clinical Research Network","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"18","key":"10.1016\/j.rvsc.2019.03.018_bb0215","doi-asserted-by":"crossref","first-page":"11947","DOI":"10.1016\/S0021-9258(18)99049-6","article-title":"The human gene for vascular endothelial growth factor","volume":"266","author":"Tischer","year":"1991","journal-title":"J. Biol. Chem."},{"issue":"6","key":"10.1016\/j.rvsc.2019.03.018_bb2000","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1016\/j.ophtha.2016.02.022","article-title":"Aflibercept, Bevacizumab, or Ranibizumab for Diabetic Macular Edema: Two-Year Results from a Comparative Effectiveness Randomized Clinical Trial","volume":"123","author":"Wells","year":"2016","journal-title":"Ophthalmology"},{"issue":"25","key":"10.1016\/j.rvsc.2019.03.018_bb0220","first-page":"635","article-title":"Comparison of topical cyclosporin and dexamethasone for the treatment of chronic superficial keratitis in dogs","volume":"137","author":"Williams","year":"1995","journal-title":"Vet.Rec."},{"issue":"10","key":"10.1016\/j.rvsc.2019.03.018_bb0225","doi-asserted-by":"crossref","first-page":"3421","DOI":"10.1021\/mp500160v","article-title":"Comparison of binding characteristics and in vitro activities of three inhibitors of vascular endothelial growth factor a","volume":"11","author":"Yang","year":"2014","journal-title":"Mol. Pharm."}],"container-title":["Research in Veterinary Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0034528818315340?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0034528818315340?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T04:20:19Z","timestamp":1758514819000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0034528818315340"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6]]},"references-count":44,"alternative-id":["S0034528818315340"],"URL":"https:\/\/doi.org\/10.1016\/j.rvsc.2019.03.018","relation":{},"ISSN":["0034-5288"],"issn-type":[{"value":"0034-5288","type":"print"}],"subject":[],"published":{"date-parts":[[2019,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"In-vitro binding analysis of anti-human vascular endothelial growth factor antibodies bevacizumab and aflibercept with canine, feline, and equine vascular endothelial growth factor","name":"articletitle","label":"Article Title"},{"value":"Research in Veterinary Science","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rvsc.2019.03.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}